Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575963 · ClinicalTrials.gov registry record · Phase 1
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
A Phase 1 study, sponsored by Actinium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02575963 is a Phase 1 study that has completed, run by Actinium Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT02575963, a Phase 1 study, has completed, sponsored by Actinium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion)
Interventions
- DRUG Spironolactone
- DRUG Cytarabine (Phase 1 only)
- BIOLOGICAL Lintuzumab-Ac225
- DRUG Furosemide (Phase 1 only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-10 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575963
The ClinicalTrials.gov registry entry for NCT02575963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actinium Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Spironolactone is the first listed.
NCT02575963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575963 about?
NCT02575963 is a clinical study titled "Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients". The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac22...
What is the current status of trial NCT02575963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-10. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02575963?
The interventions under investigation include: Spironolactone (DRUG), Cytarabine (Phase 1 only) (DRUG), Lintuzumab-Ac225 (BIOLOGICAL), Furosemide (Phase 1 only) (DRUG).
Who is sponsoring clinical trial NCT02575963?
This trial is sponsored by Actinium Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.